Friedrichs, Anette and Wenz, Roman and Pape, Daniel and Appel, Katharina S. and Bahmer, Thomas and Becker, Karsten and Bercker, Sven and Blaschke, Sabine and Braunsteiner, Josephine and Butzmann, Jana and Dahl, Egdar and Erber, Johanna and Fricke, Lisa and Geisler, Ramsia and Goepel, Siri and Gueldner, Andreas and Hagen, Marina and Hamprecht, Axel and Hansch, Stefan and Heuschmann, Peter U. and Hopff, Sina and Jensen, Bjoern-Erik Ole and Kaeding, Nadja and Koepsell, Julia and Koll, Carolin E. M. and Krawczyk, Marcin and Luecke, Thomas and Meybohm, Patrick and Milovanovic, Milena and Mitrov, Lazar and Nuernberger, Carolin and Roemmele, Christoph and Scherer, Margarete and Schmidbauer, Lena and Stecher, Melanie and Tepasse, Phil-Robin and Teufel, Andreas and Vehreschild, Joerg Janne and Winter, Christof and Witzke, Oliver and Wyen, Christoph and Hanses, Frank and Caliebe, Amke (2025) The effect of antibiotic therapy on clinical outcome in patients hospitalized with moderate COVID-19 disease: a prospective multi-center cohort study. INFECTION, 53 (6). pp. 2543-2555. ISSN 0300-8126, 1439-0973
Full text not available from this repository. (Request a copy)Abstract
PurposeThe benefit of antibiotic treatment (ABT) for patients with moderate COVID-19 is unclear and overtreatment poses the risk of adverse effects such as Clostridioides difficile infection and antibiotic resistance. This multi-center study compares health status improvement between patients with and without ABT at hospital admission.MethodsBetween March 2020 and May 2023, hospitalized adults with confirmed SARS-CoV-2 infection were recruited from the German National Pandemic Cohort Network (NAPKON), which includes patients from various hospitals across Germany. The study population included patients with moderate or severe COVID-19 at baseline. The primary objective was to compare health improvement or decline after two weeks between patients who received ABT at baseline and those who did not in the moderate COVID-19 population. The statistical analysis adjusted for confounders such as gender, age, vaccination status, clinical condition, and comorbidities. The severe COVID-19 population was investigated as a secondary objective.ResultsA total of 1,317 patients (median age 59 years; 38% women) were eligible for analysis, of whom 1,149 had moderate and 168 severe COVID-19 disease. ABT for pneumonia was administered to 467 patients with moderate and 117 with severe COVID-19. ABT at baseline was significantly associated with a higher deterioration rate after two weeks in patients with moderate COVID-19 (ABT: 292 improvement, 61 deterioration; no ABT: 429 improvement, 14 deterioration). A similar result was obtained in the multiple regression analysis where an odds ratio of 5.00 (95% confidence interval: 2.50 - 10.93) for ABT was observed.ConclusionWe found no benefit of antibiotic therapy in patients with moderate COVID-19. Use of ABT was associated with a higher likelihood of clinical deterioration.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | ; COVID-19; Rational antibiotic therapy; Clinical outcome; Moderate disease; Clinical improvement |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Abteilung für Krankenhaushygiene und Infektiologie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 25 Mar 2026 12:36 |
| Last Modified: | 25 Mar 2026 12:36 |
| URI: | https://pred.uni-regensburg.de/id/eprint/68018 |
Actions (login required)
 |
View Item |
